These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Low-molecular-weight heparin in cancer-associated thrombosis: treatment, secondary prevention, and survival. Nishioka J; Goodin S J Oncol Pharm Pract; 2007 Jun; 13(2):85-97. PubMed ID: 17873108 [TBL] [Abstract][Full Text] [Related]
3. Management of deep vein thrombosis. Chong BH Aust Fam Physician; 2001 Mar; 30(3):235-40. PubMed ID: 11301761 [TBL] [Abstract][Full Text] [Related]
4. Update in the treatment of venous thromboembolism. Garcia DA; Spyropoulos AC Semin Respir Crit Care Med; 2008 Feb; 29(1):40-6. PubMed ID: 18302085 [TBL] [Abstract][Full Text] [Related]
5. Emerging anticoagulants for the treatment of venous thromboembolism. Weitz JI Thromb Haemost; 2006 Sep; 96(3):274-84. PubMed ID: 16953267 [TBL] [Abstract][Full Text] [Related]
7. Anticoagulants and thrombolysis in the treatment of pulmonary embolism. Raskob GE Curr Opin Pulm Med; 1995 Jul; 1(4):291-7. PubMed ID: 9363067 [TBL] [Abstract][Full Text] [Related]
8. Anticoagulants: the state of the art. Gallus AS Aust Fam Physician; 1982 Jan; 11(1):14-22. PubMed ID: 7065989 [TBL] [Abstract][Full Text] [Related]
9. The role of low-molecular-weight heparins as supportive care therapy in cancer-associated thrombosis. Cunningham RS Semin Oncol; 2006 Apr; 33(2 Suppl 4):S17-25; quiz S41-2. PubMed ID: 16638457 [TBL] [Abstract][Full Text] [Related]
10. Ximelagatran for treatment and prophylaxis of recurrent events in deep vein thrombosis. Koscielny J; Kiesewetter H; Jörg I; Harenberg J Clin Appl Thromb Hemost; 2007 Jul; 13(3):299-307. PubMed ID: 17636192 [TBL] [Abstract][Full Text] [Related]
11. Outpatient management of anticoagulation therapy. du Breuil AL; Umland EM Am Fam Physician; 2007 Apr; 75(7):1031-42. PubMed ID: 17427618 [TBL] [Abstract][Full Text] [Related]
12. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials. van Doormaal FF; Raskob GE; Davidson BL; Decousus H; Gallus A; Lensing AW; Piovella F; Prins MH; Büller HR Thromb Haemost; 2009 Apr; 101(4):762-9. PubMed ID: 19350123 [TBL] [Abstract][Full Text] [Related]
13. Anticoagulant treatment of deep vein thrombosis and pulmonary embolism. Tran H; McRae S; Ginsberg J Cardiol Clin; 2008 May; 26(2):235-50, vi-vii. PubMed ID: 18406997 [TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of lower-dose unfractionated heparin for prophylaxis of deep vein thrombosis and pulmonary embolism in an Asian population. Ugaki H; Enomoto T; Fujiwara K; Kimura T; Kawasaki T Blood Coagul Fibrinolysis; 2008 Sep; 19(6):585-9. PubMed ID: 18685443 [TBL] [Abstract][Full Text] [Related]
16. Mortality as primary end point in studies of heparin thromboprophylaxis. Locke CF Am J Med; 2007 May; 120(5):e11; author reply e17-8. PubMed ID: 17466632 [No Abstract] [Full Text] [Related]
17. Venous thromboembolism prophylaxis and treatment in patients with acute stroke and traumatic brain injury. Vergouwen MD; Roos YB; Kamphuisen PW Curr Opin Crit Care; 2008 Apr; 14(2):149-55. PubMed ID: 18388676 [TBL] [Abstract][Full Text] [Related]
18. Travel-related thrombosis: is this a problem? Brenner B Isr Med Assoc J; 2006 Dec; 8(12):859-61. PubMed ID: 17216870 [No Abstract] [Full Text] [Related]
19. Low-intensity versus conventional-intensity warfarin for prevention of recurrent venous thromboembolism. Malik V; Kupfer Y; Tessler S N Engl J Med; 2003 Nov; 349(22):2164-7; author reply 2164-7. PubMed ID: 14658127 [No Abstract] [Full Text] [Related]
20. Heparin: from animal organ extract to designer drug. Middeldorp S Thromb Res; 2008; 122(6):753-62. PubMed ID: 17996279 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]